Last year, Novo Nordisk bought US company Emisphere Technologies for USD 1.8bn. Former investors in Emisphere are now suing the company's largest shareholder, MHR Fund Management, according to Fierce Pharma.
Iszo, a New York-based investment fund, accuses MHR of manipulating the Emisphere board to sell the company at an inconvenient time at an artifically low price.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.